U.S. Intravenous Solutions Companies Strategic Expansion Initiatives

Latest Updates of Companies in the U.S. Intravenous Solutions Market

See the full picture of the U.S. Intravenous Solutions Market without the complexity -Access the dashboard.

Recent Developments in the U.S. Intravenous Solutions Market

• In November 2025, Solventum announced it had entered into a definitive agreement to acquire Acera Surgical, a confidentially held bioscience organization focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.
• In May 2025, ICU Medical Inc. and Otsuka Pharmaceutical Factory, Inc. (OPF), announced the formation of Otsuka ICU Medical LLC, a novel joint venture with the goal of strengthening the IV solutions supply chain
• In April 2025, Organon, a worldwide healthcare organization with a deep expertise in biosimilars, announced that it had acquired from Biogen Inc. regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, for intravenous infusion.
• In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that have demonstrated promising initial clinical activity. The EsoBiotec Engineered NanoBody Lentiviral platform authorizes the immune system.

Supply Chain Analysis

R&D:

• Research and development (R&D) in intravenous solutions includes a rigorous process focused on design stability, sterilization validation, container compatibility, and government compliance to ensure efficacy and safety.
• Key Players: Pfizer Inc. and Grifols, S.A. 

Manufacturing Processes:

• The manufacturing processes for intravenous solutions involve water purification, mixing ingredients, microfiltration, sterile container forming and filling, terminal sterilization, and advanced quality control testing.
• Key Players: Baxter International Inc. and ICU Medical, Inc.

Patient Services:

• Patient services in intravenous (IV) solution therapy include the administration of fluids, electrolytes, medications, or nutrients directly into the bloodstream to manage dehydration, shock, or metabolic inequities
• Key Players: B. Braun Medical Inc. and Fresenius Kabi USA

Market Trends

The U.S. intravenous solutions market size was estimated at USD 5.82 billion in 2025 and is predicted to increase from USD 6.19 billion in 2026 to approximately USD 10.82 billion by 2035, expanding at a CAGR of 6.4% from 2026 to 2035. The U.S. intravenous solutions market is growing because of the rising prevalence of chronic and acute health diseases that need fluid therapy, boosted by technological development and increasing healthcare infrastructure.